Parkinson’s Disease PBMC
About: Parkinson's Disease PBMC samples are collected from clinically confirmed Parkinson's Disease donors and cryopreserved. Ideal for immune profiling and response and uncovering gene expression patterns associated with disease progression.
| Lot Number | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73016 | Parkinson's Disease | 10M | Caucasian | 75 | Male |
Repatha® (evolocumab) /140mg/every 2 weeks Finasteride /5mg/QD Alfuzosin/10mg/QD Pantoprazole/40mg/PRN Baclofen 5 mg QD- No longer taking
|
6 | |||
| 72955 | Parkinson's Disease | 10M | Caucasian | 78 | Male |
Extended release Carbidopa / Levodopa/2500mg/QID Tamsulosin/0.4mg/QD SAW PALMETTO/450mg/QD VIt D QW Vit C
|
6 | |||
| 73019 | Parkinson's Disease | 10M | Caucasian | 70 | Female |
Carbidopa/Levodopa 25/100 IR 10 tabs po QD Carbidopa/Levodopa 25/100 ER 2 tabs po QHS Selegiline 5 mg po QD Paroxetine HCL 30 mg po QD Levothyroxine 0.75 mcg po QD Fluocinolone Acetonide Cream QD Fluocinonide Topical solution PRN Restasis BID Clobetasol Propionate Cream Weekly Vitamin D3 2000 IU po QD Multivitamin po QD Melatonin 10 mg Tylenol PRN
|
4 | |||
| 69267 | Parkinson's Disease | 10M | Caucasian | 71 | Male |
Rosuvastatin 10 mg QD Cyclobenzaprine 5 mg TID PRN Indonethacin 50 mg BID Carbidopa/Levidopa 8 tabs per day Donepezil 5 mg QD Glycopyrrolate 1 mg TID PRN Entacapone 200 mg QD Vit D QW Levothyroxine 125 mcg QD Ciclopirox PRN
|
3 | |||
| 78428 | Parkinson's Disease | 10M | Male |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||||
| 78429 | Parkinson's Disease | 10M | Male |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||||
| 78430 | Parkinson's Disease | 10M | Male |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||||
| 78431 | Parkinson's Disease | 10M | Male |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||||
| 78432 | Parkinson's Disease | 10M | Male |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||||
| 78361 | Parkinson's Disease | 10M | Male |
Acetylsalicylic acid, Carbidopa/levodopa
|
1 |
High-Quality Parkinson’s Disease PBMC for Research
Parkinson’s Disease Human PBMC products are sourced from donors clinically diagnosed with Parkinson’s Disease and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on immune profiling, immune response, and gene expression patterns associated with disease progression.
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed Parkinson’s Disease donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified Parkinson’s Disease diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional Parkinson’s Disease-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in Parkinson’s Disease pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Parkinson’s Disease PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
Electronic medical records are an option to be included with the PBMC sample, as well as, flow cytometry and other phenotypic testing.
1 Answer
YES – we can often accommodate treatment-naive samples including various cancers, and you can specify immunosupression status or other requirements in the I/E criteria.
1 Answer
Self-reported infectious disease testing is always available and some of our products have additional testing.
1 Answer
HLA-typing is available for some of our PBMC products.
1 Answer
YES to both – Unique donors can be specified, and multiple vials from the same donor can be arranged. You can specify these requirements when ordering.
1 Answer
Healthy PBMCs achieve over 90% vialbity post-thaw. Although our disease-state PBMCs are processed with same stringent SOP, there is more variability depending upon disease. Learn more about our post thaw viability here. https://sanguinebio.com/pbmc-viability-quality-assurance/
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.